CY1119818T1 - Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης - Google Patents

Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης

Info

Publication number
CY1119818T1
CY1119818T1 CY20181100029T CY181100029T CY1119818T1 CY 1119818 T1 CY1119818 T1 CY 1119818T1 CY 20181100029 T CY20181100029 T CY 20181100029T CY 181100029 T CY181100029 T CY 181100029T CY 1119818 T1 CY1119818 T1 CY 1119818T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
reperfusion
ischemical
prevent
recurrent
Prior art date
Application number
CY20181100029T
Other languages
English (en)
Inventor
Maurice Mannesse
Johannes Henricus Nuijens
Frank Pieper
Maria Grazia De Simoni
Gijsbertus Johannes Ziere
Original Assignee
Pharming Intellectual Property B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B.V. filed Critical Pharming Intellectual Property B.V.
Publication of CY1119818T1 publication Critical patent/CY1119818T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τη θεραπευτική και προφυλακτική χρήση του αναστολέα C1 για την πρόληψη, μείωση και θεραπεία της βλάβης ισχαιμίας και επαναιμάτωσης. Ο αναστολέας C1 της παρούσας εφεύρεσης εξακολουθεί να είναι θεραπευτικώς αποτελεσματικός, όταν χορηγείται μετά από μια ισχαιμική περίοδο και επαναιμάτωση και επομένως είναι ιδιαίτερα χρήσιμος για απρόβλεπτες εμφανίσεις ισχαιμικής επαναιμάτωσης, όπως π.χ. ένα εγκεφαλικό επεισόδιο.
CY20181100029T 2005-12-21 2018-01-10 Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης CY1119818T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05112630 2005-12-21
US76094406P 2006-01-23 2006-01-23
EP06824316A EP1965831B1 (en) 2005-12-21 2006-12-19 Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
EP11172880.4A EP2380587B1 (en) 2005-12-21 2006-12-19 Use of C1 inhibitor for the prevention of ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
CY1119818T1 true CY1119818T1 (el) 2018-06-27

Family

ID=38016640

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100950T CY1112452T1 (el) 2005-12-21 2011-10-05 Χρηση του αναστολεα c1 για την προληψη της βλαβης εξ ισχαιμιας-επαναιματωσης
CY20181100029T CY1119818T1 (el) 2005-12-21 2018-01-10 Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100950T CY1112452T1 (el) 2005-12-21 2011-10-05 Χρηση του αναστολεα c1 για την προληψη της βλαβης εξ ισχαιμιας-επαναιματωσης

Country Status (15)

Country Link
US (3) US8071532B2 (el)
EP (2) EP1965831B1 (el)
JP (2) JP5394748B2 (el)
KR (1) KR101508668B1 (el)
AT (1) ATE516043T1 (el)
AU (1) AU2006327989B2 (el)
CA (1) CA2632400C (el)
CY (2) CY1112452T1 (el)
DK (1) DK2380587T3 (el)
HR (2) HRP20110622T1 (el)
IL (2) IL192180A (el)
NZ (1) NZ568749A (el)
PL (2) PL2380587T3 (el)
SI (1) SI2380587T1 (el)
WO (1) WO2007073186A2 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142220A1 (en) * 2002-10-17 2006-06-29 Berkel Patrick V Protein modification
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
AU2007307375B2 (en) * 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
JP5423266B2 (ja) * 2009-09-14 2014-02-19 富士電機株式会社 デジタル制御スイッチング電源装置
PL2683397T3 (pl) * 2011-03-09 2018-01-31 Csl Behring Gmbh Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN104010656B (zh) * 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AU2012318275B2 (en) * 2011-12-22 2016-05-19 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
EP2914291B1 (en) 2012-11-02 2022-02-23 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
WO2014131865A1 (en) * 2013-02-28 2014-09-04 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
DK2964255T3 (da) 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK3290046T3 (en) 2013-03-15 2019-03-18 Shire Viropharma Inc C1-INH COMPOSITIONS AND PROCEDURES FOR PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH C1-ESTERASE INHIBITOR LACK
US20160166660A1 (en) * 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
EP3215221B1 (en) * 2014-11-03 2020-02-26 Thrombolytic Science, LLC Methods and compositions for safe and effective thrombolysis
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
EP3302529A4 (en) 2015-06-03 2019-02-06 The Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING GALLENA GANGATRESIA IN NEWBORNS
US20180334493A1 (en) * 2015-11-19 2018-11-22 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
WO2018024873A1 (en) 2016-08-05 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN109641031A (zh) 2016-08-23 2019-04-16 德国杰特贝林生物制品有限公司 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
AU2018334213A1 (en) 2017-09-15 2020-03-26 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
BR112020017626A2 (pt) 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112021005228A2 (pt) 2018-10-17 2021-06-15 Csl Behring Gmbh processo para purificar c1-inh
AU2020299425A1 (en) 2019-07-04 2022-03-03 Csl Behring Gmbh Process for purifying C1-INH
KR102191500B1 (ko) 2020-03-30 2020-12-15 국립낙동강생물자원관 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
KR102217607B1 (ko) 2020-06-01 2021-02-18 국립낙동강생물자원관 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR102191452B1 (ko) 2020-06-30 2020-12-15 주식회사 에이치비헬스케어 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR20230110563A (ko) 2020-11-20 2023-07-24 체에스엘 베링 게엠베하 항체 매개 거부 반응의 치료 방법
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281341T3 (es) 1999-05-14 2007-10-01 Steffen Thiel Lectina humana recombinante que se une a manano.
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
JP2004100982A (ja) * 2002-09-05 2004-04-02 Denso Corp 熱交換器
US20060142220A1 (en) 2002-10-17 2006-06-29 Berkel Patrick V Protein modification
JP2007500741A (ja) * 2003-05-16 2007-01-18 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 一時的処置のための短い半減期を有するｃ１インヒビター
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Also Published As

Publication number Publication date
CA2632400C (en) 2016-06-07
EP2380587B1 (en) 2017-10-25
PL1965831T3 (pl) 2011-12-30
US8071532B2 (en) 2011-12-06
KR20080098001A (ko) 2008-11-06
NZ568749A (en) 2011-05-27
IL228954A (en) 2016-10-31
DK2380587T3 (en) 2017-12-04
US20080305993A1 (en) 2008-12-11
IL228954A0 (en) 2013-12-31
AU2006327989B2 (en) 2012-06-07
EP1965831A2 (en) 2008-09-10
EP2380587A1 (en) 2011-10-26
JP2009520815A (ja) 2009-05-28
US20120088728A1 (en) 2012-04-12
JP2013126992A (ja) 2013-06-27
KR101508668B1 (ko) 2015-04-06
IL192180A0 (en) 2009-02-11
HRP20110622T1 (hr) 2011-09-30
WO2007073186A2 (en) 2007-06-28
US20130244941A1 (en) 2013-09-19
WO2007073186A3 (en) 2007-08-09
AU2006327989A1 (en) 2007-06-28
SI2380587T1 (en) 2018-03-30
US9211318B2 (en) 2015-12-15
HRP20171738T1 (hr) 2018-01-26
ATE516043T1 (de) 2011-07-15
JP5394748B2 (ja) 2014-01-22
PL2380587T3 (pl) 2018-03-30
IL192180A (en) 2013-10-31
CY1112452T1 (el) 2015-12-09
CA2632400A1 (en) 2007-06-28
EP1965831B1 (en) 2011-07-13
US8415288B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
CY1119818T1 (el) Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης
HK1141231A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
SMP200900013B (it) Peptidomimetici smac utili come inibitori di iap
NO20083033L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler
NO20072665L (no) Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
IN2014DN08578A (el)
GEP20125683B (en) Serine proteases inhibitors for hcv infections treatment
NO20083032L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse
EA200602220A1 (ru) Новое применение пептидных соединений для лечения амиотрофического бокового склероза
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
NO20073783L (no) Pyrrolidininhibitorer for IAP
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
CO5570674A2 (es) Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
ATE384058T1 (de) Thiazolderivate
NZ598750A (en) Therapeutic agent for mood disorders
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
NZ598754A (en) Therapeutic agent for anxiety disorders
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
WO2009148600A3 (en) Deuterated lysine-based compounds
WO2007027230A3 (en) Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
UA89242C2 (ru) Способ лечения эндометриоза с применением ингибитора jnk, которым является производное бензотиазола
ECSP003337A (es) Pirazolalquilamidas
TW200738231A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
EA200800343A1 (ru) Ингибиторы jnk для лечения эндометриоза